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Medhekar R., Chen H.
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Objectives: To assess the validity of Medicaid Analytic Extract (MAX)-2009, 
Outpatient (OT) and Provider Characteristics (PC) data for use in mental health 
research. MethOds: Medicaid issue briefs, Medicaid managed-care enrollment 
report, MAX-PC evaluation reports and MAX-validation tables for the year 2009 were 
reviewed to assess the validity of MAX-OT and MAX-PC data. Validity of the data was 
defined in terms of availability [OT: substantial number of encounter claims; PC: 
substantial number of OT billing/servicing provider IDs], completeness [OT: number 
of claims per PME, % enrollees with encounter record, number of claims per service 
user; PC: % provider IDs with primary taxonomy code] and usability [OT: primary 
diagnoses and/or procedure code reported per record]. Each state was ranked on 
these criteria as 1: Good, 2: Fair and 3: Poor for both OT and PC data and a total 
combined-score was calculated. The states with minimum total combined-score, 
which met all the criteria, were considered appropriate for research. Results: 
Thirty-six states delivered some/all mental health services through managed care 
organizations (MCOs) and the rest relied on fee-for-service (FFS). Eleven states con-
tracting with comprehensive MCOs, 4 states contracting with behavioral health 
organizations (BHOs), and 6 FFS states have usable OT-encounter data. PC data was 
available for all 51 states, of which 15 states have usable data with > 90% claims 
with OT billing/servicing provider IDs. Twelve of these states have data with ≥ 75% 
provider IDs with primary taxonomy codes. Three comprehensive MCO states (KY, 
NJ, NY), 2 BHO states (AZ, FL) and 2 FFS states (MS, LA) met all the validity criteria 
for OT and PC files. cOnclusiOns: Although, most states provide mental health 
services through comprehensive MCOs, OT-encounter data for these services is 
usable for limited states only. Researchers should exercise caution while combining 
OT and PC files for mental health research.
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Objectives: As defined by the FDA, a Clinical Outcome Assessment (COA) directly 
or indirectly measures how patients feel or function and can be used to determine 
whether or not a drug has demonstrated to provide a treatment benefit. There are 
four types of COAs: patient-reported (PRO), observer-reported (ObsRO), clinician-
reported (ClinRO), and performance outcomes (PerfO). The aim of this research is 
to create an online database of published regulatory recommendations concerning 
the use of COAs to determine treatment benefit and to inform drug approval and 
health technology assessment (HTA) review. MethOds: All clinical guidelines pub-
lished from 1977 to 2014 by North American regulatory authorities (FDA and Health 
Canada), the European Union (EMA), and NICE, were retrieved on the corresponding 
websites and reviewed. The information was categorized as follows: guideline title, 
date of publication, guideline status (“draft” or “final/adopted”), therapeutic area and 
indication based on ICD -10 classification, guideline purpose(s), and for each COA, 
the concept of interest and context of use (e.g., targeted patient population, endpoint 
positioning and study design). Results: For the EMA, we reviewed 110 scientific 
guidelines representing 62 therapeutic indications, of which approximately more 
than half recommend COA endpoints. For the FDA, we analyzed 86 guidance repre-
senting 56 therapeutic indications, of which almost 60% recommend COA endpoints. 
For Health Canada, five guidance representing five therapeutic indications were 
retrieved. The 96 recommendations published by the NICE correspond to 75 thera-
peutic indications, and are currently under review. cOnclusiOns: This project will 
be a unique source of centralized information about how COAs are recommended 
by regulatory authorities in drug development and HTA review. It will be useful to 
observe the current trends in COAs recommended, and to integrate them as early 
as possible in the product development. The database will be available online in an 
independent website, with access by subscription.
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Objectives: Healthcare resource utilization and costs are often measured by ret-
rospective claims analyses. Using a common data model (CDM) with standardized 
variables has the ability to enhance robustness and generalizability of data and 
improve the timeliness of these studies. Given the rapidly changing treatment land-
scape for HCV, it is a prime candidate for research based on a CDM. The purpose of 
this study was to analyze healthcare resource use and costs by comorbidity status 
in patients with chronic HCV using a virtual database based on a CDM. MethOds: A 
virtual database was created with 3 large commercially available datasources using 
specifications developed by Observational Medical Outcomes Partnership (OMOP) 
CDM v4 format (www.omop.org/CDM). By employing a massively parallel processing 
(MPP) database platform we created this database with 30+ standardized variables 
as needed for this study. Utilizing this virtual database allowed for comparison of 
demographic, clinical, and healthcare utilization variables analyzed simultaneously 
across the large databases for patients with HCV. Results: Results from two of the 
databases (1 commercial/Medicare, 1 commercial only) representing more than 
212,000,000 covered lives yielded information for 97,935 patients with chronic HCV 
(n= 46,384 for database 1; n= 51,551 for database 2). Baseline demographics were 
similar between the databases. Slightly less than 10% of patients had compensated 
cirrhosis, approximately 5% had decompensated cirrhosis, and transplant percent-
were identified using a validated questionnaire. The direct medical costs of patient 
management were estimated using a micro-costing analysis, and a sensitivity analy-
sis conducted using the emergency room visits rates due to DRM reported in the 
literature. All costs are presented in 2014 US$ (US$1= R$2.70). Results: 14.6% of 
patients sought emergency care due to DRM; 58.9% of DRMs were considered pre-
ventable. Mean treatment costs were US$812.38 ± 1,417 (range US$16.04 to 9,832). 
Mean inpatient length of stay of DRM patients was (5.7 ± 8.4 days). An extrapolation 
based on all 57.106 emergency visits in the last year resulted in annual total treat-
ment costs of US$6.773 million. A sensitivity analysis resulted in US$1.043 million 
in the best-case scenario and US$12.989 milion at worst, per year. cOnclusiOns: 
This is one of the first analyses of the economic consequences of DRM in Brazil, and 
shows that DRMs leading to emergency visit and hospital admission are common 
and constitute a significant economic impact to the hospital. Efforts are necessary 
to improve pharmacotherapy and reduce preventable iatrogenic costs.
ReseaRch On MethOds – databases & Management Methods
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cOMPaRisOns and cOntRasts Of diffeRent aPPROaches in estiMating 
alzheiMeR’s disease
Yuan J., Lu K.
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Objectives: Estimating the prevalence of Alzheimer’s disease (AD) has been a chal-
lenge because it has been relying on self/proxy-reported information or based on 
diagnosis alone, yielding inconsistent and underestimated results in the published 
studies. The objective of this study was to provide a more accurate prevalence of AD, 
and to make comparisons and contrast of different approaches in ascertain demen-
tia. MethOds: A cross-sectional study was performed using the Medicare Current 
Beneficiary Survey (MCBS) 2010. The study sample consisted of Medicare beneficiar-
ies aged 65 or older. AD was ascertained by using self/proxy’s report, ICD-9-CM diag-
nosis codes in the Medicare claims; AD-targeted prescription medications identified 
from both self/proxy’s report and pharmacy claims, or using a combined sources 
of information. Prevalence was estimated using ross-sectional weights. Weighted 
Kappa coefficients were estimated. Results: The prevalence of AD varied greatly 
by using different sources of information. The prevalence of AD was dropped from 
6.8% when using a combined methodology, to 3.5% when using self/proxy’s report 
alone, 1.4% when using claims data alone, and 5.3% when based on the utilization of 
AD-target medications. Using data from AD-target medications (78%) captured more 
AD cases than using self-reported data alone (52%) and claims only (21%), which 
was observed in both community and long-term care facilities. These discrepancies 
in describing AD cases were significant. The agreement between AD-target medica-
tions and claims data was 30.7% (kappa= 0.28), 38.4% between AD-target medications 
and self/proxy’s report (kappa= 0.49), and 47.2% between self/proxy-reported and 
AD-target medications (kappa= 0.27).Compared to pharmacy claims, self-reported 
medication use provided slightly higher estimates of AD cases (48.5% vs. 40.8%; 
kappa= 0.26). cOnclusiOns: The prevalence of AD was largely underestimated by 
using self/proxy’s report or claims alone. Our findings have important implications 
for identifying AD cases, and suggested a better algorism of capturing AD. Further 
research is warranted to validate the algorisms to identify AD cases.
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Objectives: Unify and deterministically deduplicate databases’ of patients regis-
tration information coming from Information Systems of SUS in Brazil: Hospital, 
Output and Mortality Information Systems, between the years 2000-2012, to get 
an individualize data and plot patients’ lines of care during the period, enabling 
pharmacoeconomic and epidemiological studies that parameterize effectiveness 
and efficiency of public policies and embedded technologies. MethOds: Semantic 
analysis of data was performed to describe and understand different meanings 
of different fields existing in the studied bases. In addition, there were two main 
procedures, executed with database operations tools and PLSQL programming lan-
guage: cleaning and standardization of databases; registration information extrac-
tion and deterministic deduplication thereof. Both procedures were first performed 
on each database separately and after the unification of the records, was held again 
a deterministic deduplication. Results: Performed procedures allowed a decision-
making to chose fields used in data model for the unified database creation. Five 
database’s representative fields related to patients were selected: first name and 
last name; birth date; state and country code of residence. Initially, the unified 
cadastral database resulted in 570,649,706 records, after deduplication there was a 
reduction culminating in 106,433,845 records. This reduction is explained because 
these databases are not fully integrated. Moreover, there is not always agreement 
between semantic systems and in some cases changes occur in the data format 
over the period within the same system. cOnclusiOns: The results show that 
data deduplication is necessary and should be carried out thoroughly. Where the 
databases had limited patients’ registration information, the technique enabled to 
capture, in more complete basis, additional information. Futhermore, it allowed to 
identify and assist in the understanding of positive and negative aspects within 
systems and trace clinical condition of patients, enabling pharmacoeconomic and 
epidemiological studies that define effectiveness and efficiency of public policies 
and embedded technologies. As future work, is important ensure the univocity of 
records.
